News

During a multidisciplinary meeting with FDA, based on preliminary results from an ongoing Phase 1/2 study, the company received alignment on key points of the Phase 3 study design.

Interventional eyelid procedures enabled by TearCare technology delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through 6 months.

The technology provides effective, efficient evaluations when paired with the right patients

Inaugural awards honor 3 residents in ophthalmology, optometry, and retina

David Hutton of Ophthalmology Times talks with Jay Katz, MD, CMO for Glaukos, and Steven R. Sarkisian, MD, about the Glaukos iDose travoprost implant.

According to the company, if approved, OCS-01 has the potential to become the first topical eye drop and non-invasive treatment option for DME.

Physicians from the Harvard Medical School and the Kresge Eye Institute at Wayne State University in Detroit recently published details from the case.

According to the company, the NORSE EIGHT study is set to kick off during the first quarter of 2024 and the Biologics License Application in the US is likely by the end of 2024.

In this podcast, Neda Shamie, MD, and Peter J. McDonnell, MD, discuss real-world experiences, patient choices, and the nuances of integrating femtosecond laser-assisted cataract surgery into practice, offering insights into the latest developments in ophthalmology.

The companies announced they will team up to enhance patient care and workflow efficiencies with a comprehensive dry eye assessment and relief platform.

Viridian's VRDN-003, a subcutaneous therapy for thyroid eye disease, has demonstrated positive data in a Phase 1 clinical study, with an extended half-life of 40-50 days. The company plans to initiate global pivotal trials in mid-2024, aiming to transform TED treatment with less frequent dosing intervals.

In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices

Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort.

NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is the company’s lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.

According to the company, the study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of contact lens discomfort and signs of concomitant meibomian gland dysfunction.

Gather, participate, learn, socialize

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

The 24th annual Retina Fellows Forum will take place on January 25 and 26, 2024 in Chicago at the Westin Chicago River North hotel.

Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma

A team of researchers from Tokyo Medical and Dental University have developed models based on machine learning that predict long-term visual acuity in patients with high myopia, one of the top three causes of irreversible blindness in many regions of the world.

Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery.

Eric Jennings, MD, from Woolfson Eye Institute, discusses the SMARTCataract cloud-based app from Alcon and its implementation where he practices with David Hutton, Managing Editor, Ophthalmology Times.

According to the company, the acquisition will extend its leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment.

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

The case for treating keratoconus without waiting for disease progression

Glaukos Corp's iDose TR has received FDA approval for the reduction of IOP in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) following a new drug application (NDA) submission.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.